Anzeige
Meldung des Tages: Diese Goldaktie startet NI-43-101 Ressourcenschätzung – jetzt kann aus der Story Substanz werden

Viking Therapeutics Aktie News

Aktie
WKN:  A12GD6 ISIN:  US92686J1060 US-Symbol:  VKTX Branche:  Biotechnologie Land:  USA
26,555 €
+0,44 €
+1,68%
09:12:51 Uhr
Depot/Watchlist
Marktkapitalisierung *
3,55 Mrd. €
Streubesitz
32,10%
KGV
-40,65
neu: Nachhaltigkeits-Score
21 %
Index-Zuordnung
-

Viking Therapeutics News

28.08.25 - PR Newswire
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
19.08.25 - wallstreetONLINE Redaktion
Biotech-Crash: Dieser Novo-Rivale stürzt gerade um fast 40 Prozent ab!
Viking Therapeutics hat zwar positive Studiendaten gemeldet – doch die Aktie stürzt am Dienstag vorbörslich um fast 38 Prozent ab. Was ist da los?Die Aktie von Viking Therapeutics ...
19.08.25 - PR Newswire
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-​Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity PR Newswire
23.07.25 - PR Newswire
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
16.07.25 - PR Newswire
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025 PR Newswire
25.06.25 - PR Newswire
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 PR Newswire
24.04.25 - wallstreetONLINE Redaktion
Mögliche Übernahmekandidaten: Abnehmpille: Wer macht das Rennen? – Eli Lilly, Novo Nordisk oder jemand anders?
Dass eine Abnehmpille die im Markt eingeführten Spritzen ersetzen wird, das scheint schon beschlossene Sache. Nur wer wird die Nummer 1 sein? Eli Lilly oder Novo Nordisk ...
23.04.25 - PR Newswire
Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
16.04.25 - PR Newswire
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 PR Newswire
26.03.25 - PR Newswire
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-​Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity PR Newswire
11.03.25 - PR Newswire
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 PR Newswire
04.03.25 - PR Newswire
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
05.02.25 - PR Newswire
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update PR Newswire
29.01.25 - PR Newswire
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025 PR Newswire

Newssuche

Videos

newspaper
27.01.26 -8,10%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »